Related content

Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma

By Tai Cheng-Jeng  

Acta Oncologica, Vol. 48, Iss. 6, 2009-08 ,pp. : 931-932

Informa Healthcare

Access to resources Recommend Favorite

Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma

By Trask Peter  

Journal of Cancer Survivorship, Vol. 5, Iss. 3, 2011-09 ,pp. : 255-262

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET

By Negrier S.   Jäger E.   Porta C.   McDermott D.   Moore M.   Bellmunt J.   Anderson S.   Cihon F.   Lewis J.   Escudier B.   Bukowski R.  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 899-906

Humana Press, Inc

Access to resources Recommend Favorite

Case report demonstrating effectiveness of sorafenib in multiple lung and bone metastases of renal cell carcinoma

By  

Oncology Letters, Vol. 9, Iss. 3, 2015-01 ,pp. : 1409-1411

Spandidos Publications

Access to resources Recommend Favorite

Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: Results from a long-term study

By            

Oncology Letters, Vol. 3, Iss. 4, 2012-01 ,pp. : 935-939

Spandidos Publications

Access to resources Recommend Favorite